# SR-Tiget gene therapy families average six months in Milan and years of lab tests

By MarketScale Newsroom · Published 2026-11-16 · Sciences on MarketScale
Canonical: https://www.marketscale.com/industries/sciences/sr-tiget-gene-therapy-families-average-six-months-in-milan-and-years-of-lab-tests

> Ten years of SR-Tiget's Just Like Home programme put numbers on what surrounds a gene therapy: long family stays, 15 years of checkups, a regulated lab.

## Key points

- In 2025, SR-Tiget's family programme coordinated 133 follow-up visits against 17 new treatments. That gap keeps widening because each patient enters roughly 15 years of twice-yearly checkups.
- At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
- Any gene therapy service has to answer one question: who tells the lab when a child's fever pushes a blood draw from morning to afternoon? In Milan, research nurses own that handoff.

In 2025, families of children treated at Milan's San Raffaele Telethon Institute for Gene Therapy spent a combined 3,114 days in accommodation arranged for them. Fourteen of those families stayed more than 100 days in a row.

The figures come from a Fondazione Telethon feature on SR-Tiget, published November 5, which uses the tenth anniversary of Just Like Home to take a closer look at the institute's ecosystem. Just Like Home helps patients and their relatives while they live in Milan for treatment. The feature follows two separate tracks that start with every therapy. One is the family's: getting to Milan and living there for months. The other belongs to the child's blood samples, which go to a regulated lab before and after treatment to check safety and long-term effect.

For hospital leaders building a cell and gene therapy service, the feature lists in unusual detail what has to exist around an approved treatment. One piece is a logistics team that starts work before the family boards a plane. The other is a lab that keeps testing a child's cells for many years after the infusion.

## A care pathway that starts with a visa

Just Like Home was set up in late 2016, after the European Medicines Agency approved a gene therapy for ADA-SCID, built on SR-Tiget research, and it reached the European market. In earlier trials, patients were few enough that clinical staff could handle the logistics themselves. As numbers grew, and more families came from abroad, the institute needed a dedicated programme. The timing is the lesson: the support structure arrived with commercial approval, when the patient flow stopped being a handful of trial participants.

Care coordinator Margherita Levi puts the job plainly: a family that needs a treatment may run into many obstacles before it gets there. A medical visa, the cost of travel, finding somewhere to live or a language barrier can each stop a family that is already coping with a rare disease diagnosis.

So support starts before departure. Levi and her team join the first meetings with the clinicians, the family's doctor at home and the parents, so they can plan the stay around the family's actual situation. The work can cover visas, residence permits, hospital admission paperwork, travel, transfers, accommodation, language and cultural mediation, and psychological support. Professional mediators sit in on medical appointments as well as helping with day-to-day communication outside the hospital. Money for travel and living costs is available when a family needs it. Clinical care and treatment costs are a separate matter, and the programme does not pay them.

That boundary is worth copying. It keeps the cost of making treatment reachable separate from the cost of the treatment itself, so a charity or hospital budget can cover the first while payers handle the second.

The hardest part of the stay is clinical. The anniversary note says children spend about six weeks in a sterile room while parents take turns at the bedside, which is especially hard when there are siblings at home. During that period the programme offers psychological support plus caregivers, a music therapist and a somatic coach.

Fondazione Telethon says children make up most of the patients, and the typical family stays in Milan for six months on average. The anniversary note says the treatment journey may require a stay of at least four to six months, followed by hospital visits about twice a year for the 15 years after treatment. Because the support covers the whole family, it draws on care coordinators, administrative staff, research nurses, psychologists, mediators, professional carers and music therapists, and the feature describes each family as "a small project within the wider programme."

Block Field

Put the last two figures together: 133 follow-up visits against 17 treatments in 2025. Each patient is owed roughly 15 years of twice-yearly checkups, so the follow-up load builds on itself. That suggests follow-up work will keep growing even if the number of new treatments stays flat.

Levi sees the same arithmetic from the family side. Her team first met some of the children at eight months old, she says, and still sees them once they reach school age. A few have since completed school, passed their driving test or started university. A programme built for a six-month stay ends up as a relationship measured in school years.

For centres that take mostly domestic patients, much of this collapses into a social-work referral. For those drawing international referrals for ultra-rare conditions, the Milan numbers are a useful benchmark: plan coordinator time, housing and interpreters around the families already in follow-up, and the year's new treatment slots.

## A clinical lab that runs on protocols

The samples go to the SR-Tiget Clinical Laboratory, known as the TCL, for specialist analyses that routine clinical labs generally can't run. That alone tells a hospital it can't simply route gene therapy samples through its usual pathology service. Its coordinator, Matias Soncini, puts it this way: the lab takes part in clinical research, but it is not a research lab. Staff don't choose experiments. They run the analyses that clinical protocols specify, to fixed procedures, schedules and quality requirements. Many of those tests involve little automation and need the hands of an experienced wet-lab scientist.

The lab was set up to take methods invented by the research groups behind each therapy and make them usable in trials. That means validating, standardising and documenting each method so its results are reproducible and can support a regulatory filing. Some tests watch for adverse effects. Others measure trial endpoints. A central one is vector copy number: how many copies of the therapeutic gene sit in the patient's cells, and how that count changes over time. Other assays confirm that the gene's product shows up in the right cells and works.

At SR-Tiget, the average family is in Milan for six months, and the child's samples can keep reaching the lab for as long as twenty years. Some trials run a decade, and follow-up can continue after a trial closes. The TCL was formed by pulling together work that separate groups used to do, and it now has almost twenty staff. As the lab has grown, it has reorganised: rather than relying only on teams built around single diseases, it now also groups staff by area of expertise, including molecular biology, cell biology and genetics. Organising by expertise suggests the workload has grown beyond what one team per disease can handle.

For a sense of what years of consistent measurement produce, look at a different SR-Tiget programme. These figures belong to etu-cel, the institute's gene therapy for Wiskott-Aldrich syndrome (WAS), a rare genetic disorder of the immune system and platelets; they are not Just Like Home or TCL numbers. BioXconomy, describing a 2026 New England Journal of Medicine paper that drew on an eight-patient Phase I/II trial and a ten-patient Phase III trial, said the rate of two severe infections per patient per year dropped to 0.15 after treatment, and severe bleeding dropped from two incidents to 0.80 per patient per year.

How the data were gathered mattered as much as the result. Alessandro Aiuti, who has led etu-cel's development at SR-Tiget, said regulators accepted a mixture of Phase I, II and III and expanded-access data pooled together, "because the quality of the data ... was good. It was consistent." Closely matched protocols made like-for-like comparison possible, which helped a tiny patient population carry the weight of an approval.

In ultra-rare disease, then, how consistently a lab measures things over many years becomes part of the evidence. A lab built to run the same validated assay the same way for a decade is building a regulatory asset.

Hiring follows from that. The TCL looks for people with a researcher's technical skills who want a career outside academia, built on validated procedures, operational responsibility and schedules set by clinical need. In return it offers steadier employment and a direct link to patients.

Soncini's own path ran from academic project leader to pharmaceutical quality control, where he learned to manage regulated labs, before he joined. Levi's ran through international relations, communications and child protection before she joined Fondazione Telethon in 2018; her role requires knowledge of health and social care networks and close attention to professional boundaries. Lab directors short on staff who can work to GMP-style discipline (the documented, regulated procedures drug manufacturers follow) could use that pitch: stable work, defined procedures and a patient on the other end.

## Research nurses hold the two schedules together

Just Like Home and the TCL don't work side by side day to day. Research nurses connect them. They manage each patient's clinical schedule and tell the lab when samples will be drawn and when they should arrive.

Those plans change often. Many patients are babies or young children, and a fever or infection can push a blood draw back. A sample due in the morning may arrive in the afternoon, and the lab has to reshuffle its day. In practice, the patient's condition sets the testing schedule, not the lab's planner.

On the bench, technicians handle coded tubes and produce numbers without meeting the families, so the institute uses all-staff meetings, personal stories and photos of patients to show them who the results are for.

> Our job is not simply to generate a number or a test result. There is a child at the other end, and clinicians need that information to continue looking after them., Matias Soncini, SR-Tiget Clinical Laboratory coordinator, speaking to Fondazione Telethon

The feature names the image that does the most work: a child running who would otherwise have progressively lost their abilities. For staff whose work can feel repetitive and removed from clinical care, that is the link between a vector copy number and a patient. It also points to the practical question any service has to answer, because the same coded tube that hides the child also hides the clinical reason it arrived late.

Block Field

## Shorter trips, the same long follow-up

BioXconomy reported that the first American patient was set to receive etu-cel at the University of California, San Francisco, in the first week of November, through a partnership between Fondazione Telethon and the US nonprofit Orphan Therapeutics Accelerator. Aiuti described the process as taking less than two months from cell collection to infusion, followed by regulator-required check-ups over months and years. Collecting the patient's own stem cells typically takes one to two days, and the cells travel to the manufacturer and back rather than the family travelling to Milan.

Moving treatment closer to home shrinks the relocation problem. The sample-tracking problem stays the same size, and it lands on whichever hospital and lab take the patient on.

Milan's own pipeline is still filling. Speaking at the International GM1 Virtual Community Conference on October 2, Dr. Maria Ester Bernardo of SR-Tiget outlined a platform approach to stem cell gene therapy that covers several lysosomal diseases. According to Cure GM1's recap, such a trial could begin around mid-2027 if it wins approval. A separate arm for GLB1-related disorders, GM1 among them, would be added later, after the first group.

Each new trial could bring more families to Milan and add years of samples to the TCL's schedule.

## Sources

- [Gene Therapy at SR-Tiget: Where Research Meets Care](https://www.fondazionetelethon.it/en/stories-and-news/news/from-research/where-research-meets-care-inside-sr-tigets-ecosystem/)
- [Ten years of “Just like Home”: supporting families ...](https://www.fondazionetelethon.it/en/stories-and-news/news/from-telethon-foundation/ten-years-of-just-like-home-supporting-families-throughout-the-treatment-journey/)
- [From Research](https://www.fondazionetelethon.it/en/stories-and-news/news/from-research/)
- [Nonprofit gene therapy for Wiskott-Aldrich syndrome lands ...](https://www.bioxconomy.com/modalities/nonprofit-gene-therapy-wiskott-aldrich-syndrome-us-shores)
- [Highlights from the 2026 International GM1 Virtual ...](https://www.curegm1.org/gm1-conference-2026-highlights/)

Tags: SR-Tiget, Fondazione Telethon, gene therapy, cell and gene therapy, rare disease, clinical laboratory, patient logistics, hospital operations, clinical trials, long-term follow-up, Waskyra, healthcare workforce

---
Source: MarketScale, https://www.marketscale.com/industries/sciences/sr-tiget-gene-therapy-families-average-six-months-in-milan-and-years-of-lab-tests. Published for AI indexing and citation; cite the canonical URL. Site guide for agents: https://www.marketscale.com/llms.txt
